Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the ...

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

These drugmakers can perform well despite competition and patent cliffs facing them. Both have excellent dividend programs and have increased their payouts at a good clip. Broader equities almost ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1 ...

BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board ...

The downgrade follows a 24% rise in BioNTech’s shares to $113 from December lows of $92, a move that outpaced the 4% gain in the S&P Biotechnology Select Industry Index over the same period. Leerink ...

High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ:BNTX), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a ...

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and boosted its price target from ...

With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets ( [3]) , companies demonstrating disciplined pivotal execution and FDA ...